作者
Norio Akuta, Yusuke Kawamura, Chizuru Watanabe, Akihiro Nishimura, Minoru Okubo, Yasumichi Mori, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
发表日期
2019/5
期刊
Hepatology Research
卷号
49
期号
5
页码范围
531-539
简介
Aim
The aim of this study was to investigate the therapeutic potential of sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective therapeutic option for non‐alcoholic fatty liver disease (NAFLD).
Methods
In this prospective study, nine patients with NAFLD complicated by type 2 diabetes mellitus (DM), were introduced to the regimen of canagliflozin 100 mg once daily for 24 weeks and were evaluated by liver histology at pretreatment and at 24 weeks after the start of treatment. The primary outcome was histological improvement, defined as a decrease in NAFLD activity score of one point or more without worsening in fibrosis stage. Glucose metabolism was evaluated based on the meal tolerance test. The usefulness of extracellular and exosome microRNA‐122 (miR‐122) as early predictors of histological improvement was investigated.
Results
All of the nine patients achieved histological improvement …
学术搜索中的文章
N Akuta, Y Kawamura, C Watanabe, A Nishimura… - Hepatology Research, 2019
N Akuta, Y Kawamura, C Watanabe, A Nishimura… - Hepatol Res, 2018